Alnylam Pharmaceuticals (ALNY) Financials

$419.26 +17.46 (+4.34%)

As of 01:30 PM Eastern

Annual Income Statements for Alnylam Pharmaceuticals

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-290	-410	-491	-761	-886	-858	-853	-1,131	-440	-278
Consolidated Net Income / (Loss)	-290	-410	-491	-761	-886	-858	-853	-1,131	-440	-278
Net Income / (Loss) Continuing Operations	-290	-410	-491	-761	-886	-858	-853	-1,131	-440	-278
Total Pre-Tax Income	-290	-410	-491	-761	-885	-856	-852	-1,127	-434	-377
Total Operating Income	-296	-425	-500	-815	-939	-828	-709	-785	-282	-177
Total Gross Profit	41	47	90	73	195	415	704	869	1,518	1,925
Total Revenue	41	47	90	75	220	493	844	1,037	1,828	2,248
Operating Revenue	41	47	90	75	220	493	844	1,037	1,828	2,248
Total Cost of Revenue	0.00	0.00	0.00	1.80	25	78	140	169	310	323
Operating Cost of Revenue	-	-	0.00	1.80	25	78	140	169	310	323
Total Operating Expenses	337	472	590	888	1,134	1,243	1,413	1,654	1,800	2,102
Selling, General & Admin Expense	61	89	199	382	479	588	621	771	796	976
Research & Development Expense	276	382	391	505	655	655	792	883	1,004	1,126
Total Other Income / (Expense), net	5.94	14	9.21	54	54	-27	-143	-342	-151	-200
Interest Expense	-	-	-	0.00	0.00	84	143	233	121	142
Interest & Investment Income	5.86	8.31	12	29	33	-	1.58	25	96	122
Other Income / (Expense), net	0.08	6.17	-3.02	25	21	57	-2.05	-134	-126	-181
Income Tax Expense	-	0.00	0.00	0.82	0.86	2.68	0.68	4.16	6.73	-99
Basic Earnings per Share	($3.45)	($4.79)	($5.42)	($7.57)	($8.11)	($7.46)	($7.20)	($9.30)	($3.52)	($2.18)
Weighted Average Basic Shares Outstanding	83.99M	85.60M	90.55M	100.59M	109.26M	114.99M	118.45M	121.69M	124.91M	127.65M
Diluted Earnings per Share	($3.45)	($4.79)	($5.42)	($7.57)	($8.11)	($7.46)	($7.20)	($9.30)	($3.52)	($2.18)
Weighted Average Diluted Shares Outstanding	83.99M	85.60M	90.55M	100.59M	109.26M	114.99M	118.45M	121.69M	124.91M	127.65M
Weighted Average Basic & Diluted Shares Outstanding	83.99M	85.60M	90.55M	100.59M	109.26M	114.99M	120.21M	124.13M	125.95M	129.46M

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-406	-207	-174	-276	148	-138	-66	-17	-112	-84	-57
Consolidated Net Income / (Loss)	-406	-207	-174	-276	148	-138	-66	-17	-112	-84	-57
Net Income / (Loss) Continuing Operations	-406	-207	-174	-276	148	-138	-66	-17	-112	-84	-57
Total Pre-Tax Income	-406	-207	-172	-274	151	-138	-64	-11	-109	-194	-42
Total Operating Income	-258	-189	-150	-230	214	-116	-43	49	-77	-105	18
Total Gross Profit	223	284	264	233	666	354	428	591	415	490	523
Total Revenue	264	335	319	319	751	440	494	660	501	593	594
Operating Revenue	264	335	319	319	751	440	494	660	501	593	594
Total Cost of Revenue	41	51	55	85	84	86	66	69	86	103	71
Operating Cost of Revenue	41	51	55	85	84	86	66	69	86	103	71
Total Operating Expenses	481	472	414	463	452	470	472	543	492	596	505
Selling, General & Admin Expense	236	210	184	215	199	198	211	248	221	295	240
Research & Development Expense	245	262	231	249	253	272	261	294	271	300	265
Total Other Income / (Expense), net	-148	-18	-23	-44	-63	-21	-20	-60	-32	-89	-60
Interest Expense	118	30	29	30	31	31	35	33	34	39	39
Interest & Investment Income	7.82	14	19	21	25	30	30	29	32	31	29
Other Income / (Expense), net	-38	-2.57	-12	-35	-58	-20	-15	-56	-30	-81	-50
Income Tax Expense	-0.02	0.47	1.74	1.82	2.99	0.18	2.35	5.72	2.91	-110	16
Basic Earnings per Share	($3.32)	($1.69)	($1.40)	($2.21)	$1.18	($1.09)	($0.52)	($0.13)	($0.87)	($0.66)	($0.44)
Weighted Average Basic Shares Outstanding	122.17M	121.69M	124.11M	124.66M	125.22M	124.91M	126.14M	126.73M	128.59M	127.65M	129.68M
Diluted Earnings per Share	($3.32)	($1.69)	($1.40)	($2.21)	$1.15	($1.06)	($0.52)	($0.13)	($0.87)	($0.66)	($0.44)
Weighted Average Diluted Shares Outstanding	122.17M	121.69M	124.11M	124.66M	131.34M	124.91M	126.14M	126.73M	128.59M	127.65M	129.68M
Weighted Average Basic & Diluted Shares Outstanding	123.03M	124.13M	124.53M	125.00M	125.49M	125.95M	126.49M	128.38M	128.98M	129.46M	130.39M

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	106	13	452	-224	127	-51	323	46	-54	154
Net Cash From Operating Activities	-189	-308	-383	-563	-278	-615	-642	-541	104	-8.31
Net Cash From Continuing Operating Activities	-189	-308	-383	-563	-278	-615	-642	-541	104	-8.31
Net Income / (Loss) Continuing Operations	-290	-410	-491	-761	-886	-858	-853	-1,131	-440	-278
Consolidated Net Income / (Loss)	-290	-410	-491	-761	-886	-858	-853	-1,131	-440	-278
Depreciation Expense	19	15	12	15	17	35	48	44	54	57
Non-Cash Adjustments To Reconcile Net Income	47	72	95	170	164	170	227	445	345	402
Changes in Operating Assets and Liabilities, net	35	15	1.48	14	390	-1.44	-105	101	145	-189
Net Cash From Investing Activities	-321	143	-290	273	-418	-436	-273	169	-336	-117
Net Cash From Continuing Investing Activities	-321	143	-290	273	-418	-436	-273	169	-336	-117
Purchase of Property, Plant & Equipment	-13	-65	-104	-127	-140	-70	-76	-72	-62	-34
Purchase of Investments	-1,035	-909	-903	-1,119	-2,076	-2,052	-1,698	-2,075	-1,882	-1,712
Sale and/or Maturity of Investments	727	1,116	717	1,519	1,805	1,692	1,506	2,322	1,612	1,630
Other Investing Activities, net	-	-	0.00	0.00	-7.00	-5.30	-4.20	-4.69	-4.44	-0.12
Net Cash From Financing Activities	616	178	1,125	65	823	995	1,247	426	172	294
Net Cash From Continuing Financing Activities	616	178	1,125	65	823	995	1,247	426	172	294
Repayment of Debt	-	-	-120	0.00	-	0.00	500	-762	0.00	0.00
Issuance of Debt	-	150	-	0.00	0.00	200	0.00	1,016	0.00	0.00
Issuance of Common Equity	617	28	1,245	65	853	300	246	259	147	303
Other Financing Activities, net	0.38	-0.60	-	0.00	-30	495	501	-88	25	-8.79
Effect of Exchange Rate Changes	-	-	-	-	-0.08	4.92	-9.02	-7.43	6.39	-15
Cash Interest Paid	-	1.10	2.43	-	0.17	0.00	25	45	32	68
Cash Income Taxes Paid	0.07	0.11	0.11	-	-	-	-	2.65	6.02	14

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	498	-207	-194	-14	375	-220	-130	286	131	-134	54
Net Cash From Operating Activities	-115	-132	-166	-59	359	-30	-82	124	44	-95	-118
Net Cash From Continuing Operating Activities	-115	-132	-166	-59	359	-30	-82	124	44	-95	-118
Net Income / (Loss) Continuing Operations	-406	-207	-174	-276	148	-138	-66	-17	-112	-84	-57
Consolidated Net Income / (Loss)	-406	-207	-174	-276	148	-138	-66	-17	-112	-84	-57
Depreciation Expense	11	14	14	13	13	13	14	15	14	14	14
Non-Cash Adjustments To Reconcile Net Income	237	61	67	101	108	69	77	120	78	127	93
Changes in Operating Assets and Liabilities, net	33	31	-86	93	80	58	-118	-3.84	50	-117	-168
Net Cash From Investing Activities	314	-140	-76	-8.71	-11	-241	-68	34	-30	-53	114
Net Cash From Continuing Investing Activities	314	-140	-76	-8.71	-11	-241	-68	34	-30	-53	114
Purchase of Property, Plant & Equipment	-17	-22	-14	-16	-17	-15	-13	-8.02	-4.19	-9.09	-8.97
Purchase of Investments	-223	-723	-485	-386	-421	-589	-460	-316	-450	-487	-450
Sale and/or Maturity of Investments	558	605	423	394	432	364	405	358	424	443	573
Net Cash From Financing Activities	297	63	46	53	33	39	29	131	103	31	44
Net Cash From Continuing Financing Activities	297	63	46	53	33	39	29	131	103	31	44
Issuance of Common Equity	153	57	42	49	25	31	26	133	108	36	49
Other Financing Activities, net	-111	7.50	4.00	4.00	8.33	8.33	3.05	-1.28	-5.28	-5.28	-5.28
Effect of Exchange Rate Changes	2.02	1.62	2.18	-0.13	-6.55	11	-9.94	-3.12	15	-17	14
Cash Interest Paid	15	1.30	14	3.22	9.55	5.44	31	8.16	16	12	67
Cash Income Taxes Paid	-	-	-	-	-	-	-	-	-	-	2.97

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	1,387	1,263	1,995	1,575	2,395	3,407	3,643	3,546	3,830	4,240
Total Current Assets	1,105	672	1,765	1,201	1,716	2,615	2,809	2,692	2,983	3,295
Cash & Equivalents	181	194	645	420	547	497	820	866	813	966
Short-Term Investments	900	433	1,045	664	989	1,378	1,616	1,326	1,627	1,728
Accounts Receivable	8.30	23	34	19	43	102	199	238	328	405
Inventories, net	-	-	-	24	56	75	86	129	89	79
Prepaid Expenses	17	22	40	74	80	63	88	133	126	117
Plant, Property, & Equipment, net	28	115	182	321	425	465	502	523	526	503
Total Noncurrent Assets	253	476	48	53	254	327	333	331	321	442
Long-Term Investments	252	475	44	45	15	41	41	49	49	69
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	-	10	117
Other Noncurrent Operating Assets	1.47	1.56	4.17	8.62	239	287	292	281	262	256
Total Liabilities & Shareholders' Equity	1,387	1,263	1,995	1,575	2,395	3,407	3,643	3,546	3,830	4,240
Total Liabilities	122	343	228	273	956	2,391	3,055	3,705	4,051	4,173
Total Current Liabilities	62	132	144	179	353	585	696	768	968	1,186
Accounts Payable	17	54	28	60	50	52	73	98	56	88
Accrued Expenses	29	42	72	113	197	356	395	545	713	887
Current Deferred Revenue	17	35	44	7.07	78	127	149	42	103	55
Other Current Liabilities	-	-	-	0.00	28	50	78	82	97	155
Total Noncurrent Liabilities	60	211	84	93	604	1,614	2,359	2,937	3,083	2,987
Long-Term Debt	-	150	30	30	0.00	-	676	1,017	1,021	1,025
Noncurrent Deferred Revenue	58	58	50	58	318	225	152	194	188	0.00
Other Noncurrent Operating Liabilities	1.30	3.07	4.35	4.97	285	1,389	1,531	1,726	1,874	1,962
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,265	920	1,766	1,302	1,439	1,016	588	-158	-221	67
Total Preferred & Common Equity	1,265	920	1,766	1,302	1,439	1,016	588	-158	-221	67
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,265	920	1,766	1,302	1,439	1,016	588	-158	-221	67
Common Stock	2,507	2,610	3,949	4,176	5,202	5,645	6,060	6,456	6,812	7,389
Retained Earnings	-1,247	-1,657	-2,148	-2,841	-3,727	-4,585	-5,438	-6,569	-7,010	-7,288
Accumulated Other Comprehensive Income / (Loss)	4.37	-33	-34	-33	-37	-44	-33	-45	-23	-35

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	3,535	3,392	3,402	3,839	3,824	4,010	4,205	4,214
Total Current Assets	2,691	2,541	2,524	2,985	2,989	3,173	3,355	3,268
Cash & Equivalents	1,073	672	658	1,033	682	968	1,100	1,020
Short-Term Investments	1,192	1,398	1,400	1,373	1,689	1,656	1,680	1,613
Accounts Receivable	185	219	221	325	321	309	354	418
Inventories, net	115	132	100	96	94	84	76	66
Prepaid Expenses	126	119	145	158	202	155	145	152
Plant, Property, & Equipment, net	515	523	527	526	523	517	507	499
Total Noncurrent Assets	330	328	351	328	312	320	343	447
Long-Term Investments	49	49	49	49	49	49	69	69
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	107
Other Noncurrent Operating Assets	280	279	301	279	263	270	274	271
Total Liabilities & Shareholders' Equity	3,535	3,392	3,402	3,839	3,824	4,010	4,205	4,214
Total Liabilities	3,603	3,651	3,811	4,005	4,044	4,013	4,173	4,098
Total Current Liabilities	773	673	789	950	942	1,055	1,221	1,076
Accounts Payable	41	62	60	74	78	74	71	97
Accrued Expenses	511	509	599	713	699	809	946	704
Current Deferred Revenue	144	36	55	77	77	69	71	28
Other Current Liabilities	77	67	76	86	88	104	133	246
Total Noncurrent Liabilities	2,830	2,978	3,022	3,055	3,102	2,957	2,952	3,023
Long-Term Debt	1,016	1,018	1,019	1,020	1,022	1,023	1,024	1,026
Other Noncurrent Operating Liabilities	1,681	1,769	1,809	1,839	1,895	1,932	1,927	1,997
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-68	-259	-408	-166	-219	-3.07	32	115
Total Preferred & Common Equity	-68	-259	-408	-166	-219	-3.07	32	115
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-68	-259	-408	-166	-219	-3.07	32	115
Common Stock	6,338	6,523	6,648	6,738	6,883	7,124	7,261	7,498
Retained Earnings	-6,362	-6,743	-7,019	-6,872	-7,076	-7,092	-7,204	-7,345
Accumulated Other Comprehensive Income / (Loss)	-44	-39	-37	-32	-27	-35	-25	-38

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-18.72%	14.75%	90.66%	-16.69%	193.36%	124.28%	71.31%	22.88%	76.23%	22.97%
EBITDA Growth	29.23%	-45.65%	-21.80%	-57.71%	-11.57%	19.40%	10.86%	-40.86%	59.56%	14.97%
EBIT Growth	26.60%	-41.39%	-20.24%	-57.01%	-16.30%	16.07%	7.83%	-29.34%	55.63%	12.34%
NOPAT Growth	26.91%	-43.44%	-17.78%	-62.91%	-15.31%	11.81%	14.46%	-10.78%	64.06%	37.31%
Net Income Growth	19.51%	-41.38%	-19.69%	-55.13%	-16.37%	3.14%	0.64%	-32.64%	61.08%	36.82%
EPS Growth	28.87%	-38.84%	-13.15%	-39.67%	-7.13%	8.01%	3.49%	-29.17%	62.15%	38.07%
Operating Cash Flow Growth	-14.19%	-62.68%	-24.40%	-46.98%	50.51%	-120.87%	-4.35%	15.65%	119.24%	-107.98%
Free Cash Flow Firm Growth	51.25%	-85.48%	-32.94%	-60.46%	51.88%	104.50%	-42.16%	-4,357.02%	128.50%	-230.57%
Invested Capital Growth	-68.11%	53.62%	297.26%	227.96%	-155.32%	-530.12%	-71.36%	-14.06%	-22.09%	1.02%
Revenue Q/Q Growth	-28.61%	26.58%	29.48%	-18.40%	29.95%	22.91%	12.67%	7.96%	6.07%	7.33%
EBITDA Q/Q Growth	-19.40%	-4.89%	-6.99%	-9.62%	-7.04%	10.94%	-3.27%	-0.48%	2.89%	-45.28%
EBIT Q/Q Growth	-18.75%	-4.17%	-6.64%	-10.52%	-7.26%	9.34%	-2.93%	3.51%	11.77%	-15.98%
NOPAT Q/Q Growth	-18.78%	-5.71%	-6.81%	-9.85%	-9.02%	11.14%	-0.05%	0.75%	20.38%	5.98%
Net Income Q/Q Growth	-31.41%	-5.73%	-6.35%	-10.00%	-7.88%	3.66%	-1.78%	4.31%	13.66%	16.28%
EPS Q/Q Growth	-45.57%	-5.51%	-3.24%	-8.76%	-4.38%	4.36%	-0.84%	4.81%	15.18%	15.50%
Operating Cash Flow Q/Q Growth	-9.51%	-8.95%	-6.90%	-9.20%	-19.55%	10.59%	-4.39%	3.25%	5,179.07%	-114.70%
Free Cash Flow Firm Q/Q Growth	-3.81%	-12.41%	-4.44%	-3.61%	-38.06%	111.17%	-77.55%	-3.45%	949.02%	-337.48%
Invested Capital Q/Q Growth	-27.09%	16.85%	4.91%	-10.37%	12.81%	-9.95%	-2.84%	-1.22%	-5.43%	6.77%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	97.59%	88.60%	84.16%	83.40%	83.73%	83.02%	85.62%
EBITDA Margin	-673.73%	-855.16%	-546.33%	-1,034.19%	-393.33%	-141.35%	-73.55%	-84.32%	-19.35%	-13.38%
Operating Margin	-720.27%	-900.33%	-556.20%	-1,087.56%	-427.50%	-168.09%	-83.94%	-75.68%	-15.43%	-7.87%
EBIT Margin	-720.08%	-887.25%	-559.56%	-1,054.54%	-418.07%	-156.46%	-84.18%	-88.61%	-22.31%	-15.90%
Profit (Net Income) Margin	-705.83%	-869.63%	-545.95%	-1,016.58%	-403.24%	-174.15%	-101.01%	-109.04%	-24.08%	-12.37%
Tax Burden Percent	100.00%	100.00%	100.00%	100.11%	100.10%	100.31%	100.08%	100.37%	101.55%	73.71%
Interest Burden Percent	98.02%	98.01%	97.57%	96.30%	96.36%	110.96%	119.90%	122.60%	106.29%	105.56%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-2,294.21%	-430.59%	-1,450.22%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-2,283.60%	-416.95%	-1,432.97%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	2,257.67%	380.96%	1,385.55%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-26.36%	-37.54%	-36.54%	-49.63%	-64.66%	-69.92%	-106.31%	-526.14%	232.40%	362.29%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-716.28%	-537.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-24.00%	-31.59%	-30.89%	-44.26%	-46.28%	-26.58%	-20.16%	-25.57%	-11.06%	-8.86%
Return on Assets (ROA)	-23.52%	-30.96%	-30.14%	-42.67%	-44.64%	-29.58%	-24.19%	-31.47%	-11.94%	-6.89%
Return on Common Equity (ROCE)	-26.36%	-37.54%	-36.54%	-49.63%	-64.66%	-69.92%	-106.31%	-526.14%	232.40%	362.29%
Return on Equity Simple (ROE_SIMPLE)	-22.94%	-44.57%	-27.79%	-58.49%	-61.59%	-84.46%	-144.99%	714.91%	199.53%	-414.62%
Net Operating Profit after Tax (NOPAT)	-207	-297	-350	-570	-658	-580	-496	-550	-198	-124
NOPAT Margin	-504.19%	-630.23%	-389.34%	-761.30%	-299.25%	-117.66%	-58.75%	-52.97%	-10.80%	-5.51%
Net Nonoperating Expense Percent (NNEP)	-7.18%	-9.89%	-10.60%	-13.64%	-17.25%	-17.00%	-20.24%	-38.45%	-18.03%	-9.63%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-64.00%	-24.69%	-11.34%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	2.41%	11.40%	15.84%	16.60%	16.27%	16.98%	14.38%
SG&A Expenses to Revenue	147.48%	189.47%	221.73%	510.44%	217.98%	119.39%	73.51%	74.29%	43.52%	43.39%
R&D to Revenue	672.79%	810.86%	434.46%	674.72%	298.12%	132.86%	93.83%	85.12%	54.94%	50.09%
Operating Expenses to Revenue	820.27%	1,000.33%	656.20%	1,185.16%	516.10%	252.25%	167.34%	159.40%	98.46%	93.48%
Earnings before Interest and Taxes (EBIT)	-296	-418	-503	-790	-919	-771	-711	-919	-408	-358
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-277	-403	-491	-775	-864	-697	-621	-875	-354	-301
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.31	3.49	6.67	5.66	8.93	14.86	34.48	0.00	0.00	452.40
Price to Tangible Book Value (P/TBV)	6.31	3.49	6.67	5.66	8.93	14.86	34.48	0.00	0.00	452.40
Price to Revenue (P/Rev)	194.10	68.13	131.03	98.34	58.43	30.64	24.02	28.18	13.14	13.50
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	162.81	30.87	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	161.68	47.95	112.08	83.66	51.37	26.75	21.89	27.00	12.34	12.73
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	216.53	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	856.53	2,075.70	0.00	208.74	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.16	0.02	0.02	0.00	0.00	1.15	-6.43	-4.63	15.27
Long-Term Debt to Equity	0.00	0.16	0.02	0.02	0.00	0.00	1.15	-6.43	-4.63	15.27
Financial Leverage	-1.05	-1.05	-0.99	-0.91	-0.97	-1.33	-2.20	-7.04	7.11	20.88
Leverage Ratio	1.12	1.21	1.21	1.16	1.45	2.36	4.39	16.72	-19.47	-52.55
Compound Leverage Factor	1.10	1.19	1.18	1.12	1.40	2.62	5.27	20.50	-20.69	-55.47
Debt to Total Capital	0.00%	14.02%	1.67%	2.25%	0.00%	0.00%	53.46%	118.43%	127.58%	93.85%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	14.02%	1.67%	2.25%	0.00%	0.00%	53.46%	118.43%	127.58%	93.85%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	85.98%	98.33%	97.75%	100.00%	100.00%	46.54%	-18.43%	-27.58%	6.15%
Debt to EBITDA	0.00	-0.37	-0.06	-0.04	0.00	0.00	-1.09	-1.16	-2.89	-3.41
Net Debt to EBITDA	0.00	2.36	3.47	1.42	0.00	0.00	2.90	1.40	4.15	5.78
Long-Term Debt to EBITDA	0.00	-0.37	-0.06	-0.04	0.00	0.00	-1.09	-1.16	-2.89	-3.41
Debt to NOPAT	0.00	-0.50	-0.09	-0.05	0.00	0.00	-1.36	-1.85	-5.17	-8.28
Net Debt to NOPAT	0.00	3.20	4.87	1.93	0.00	0.00	3.63	2.23	7.43	14.04
Long-Term Debt to NOPAT	0.00	-0.50	-0.09	-0.05	0.00	0.00	-1.36	-1.85	-5.17	-8.28
Altman Z-Score	38.27	3.25	29.64	12.84	5.39	2.02	2.18	2.23	1.75	2.81
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	17.80	5.10	12.23	6.69	4.87	4.47	4.04	3.51	3.08	2.78
Quick Ratio	17.53	4.94	11.96	6.14	4.48	3.38	3.79	3.16	2.86	2.61
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-180	-333	-443	-711	-342	15	8.90	-379	108	-141
Operating Cash Flow to CapEx	-1,460.54%	-476.63%	-367.33%	-443.40%	-198.66%	-874.01%	-840.22%	-751.15%	167.42%	-24.25%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.18	0.06	-1.63	0.89	-0.99
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	-7.28	-4.49	-2.33	0.86	-0.06
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-8.11	-5.02	-2.64	0.35	-0.30
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.03	0.04	0.06	0.04	0.11	0.17	0.24	0.29	0.50	0.56
Accounts Receivable Turnover	1.70	2.98	3.14	2.84	7.12	6.78	5.61	4.75	6.46	6.13
Inventory Turnover	0.00	0.00	0.00	0.00	0.62	1.19	1.73	1.57	2.85	3.86
Fixed Asset Turnover	1.66	0.66	0.61	0.30	0.59	1.11	1.75	2.02	3.48	4.37
Accounts Payable Turnover	0.00	0.00	0.00	0.04	0.46	1.53	2.24	1.97	4.04	4.49
Days Sales Outstanding (DSO)	214.20	122.41	116.38	128.55	51.30	53.85	65.06	76.79	56.47	59.51
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	585.58	307.59	210.40	232.78	128.23	94.62
Days Payable Outstanding (DPO)	0.00	0.00	0.00	8,918.70	798.04	238.14	163.29	185.42	90.32	81.23
Cash Conversion Cycle (CCC)	214.20	122.41	116.38	-8,790.15	-161.16	123.29	112.17	124.15	94.39	72.90
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-68	-31	62	203	-112	-708	-1,213	-1,383	-1,689	-1,671
Invested Capital Turnover	-0.76	-0.95	5.89	0.57	4.85	-1.20	-0.88	-0.80	-1.19	-1.34
Increase / (Decrease) in Invested Capital	-27	36	93	141	-315	-595	-505	-171	-306	17
Enterprise Value (EV)	6,645	2,261	10,077	6,267	11,289	13,185	18,481	28,013	22,553	28,612
Market Capitalization	7,977	3,213	11,781	7,366	12,840	15,100	20,282	29,238	24,021	30,350
Book Value per Share	$14.93	$10.72	$19.05	$12.89	$12.90	$8.75	$4.92	($1.29)	($1.76)	$0.52
Tangible Book Value per Share	$14.93	$10.72	$19.05	$12.89	$12.90	$8.75	$4.92	($1.29)	($1.76)	$0.52
Total Capital	1,265	1,070	1,796	1,332	1,439	1,016	1,264	859	800	1,092
Total Debt	0.00	150	30	30	0.00	0.00	676	1,017	1,021	1,025
Total Long-Term Debt	0.00	150	30	30	0.00	0.00	676	1,017	1,021	1,025
Net Debt	-1,332	-952	-1,705	-1,099	-1,551	-1,915	-1,801	-1,225	-1,468	-1,738
Capital Expenditures (CapEx)	13	65	104	127	140	70	76	72	62	34
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-37	-87	-70	-63	-173	155	-323	-268	-424	-585
Debt-free Net Working Capital (DFNWC)	1,043	540	1,620	1,021	1,363	2,030	2,113	1,924	2,015	2,109
Net Working Capital (NWC)	1,043	540	1,620	1,021	1,363	2,030	2,113	1,924	2,015	2,109
Net Nonoperating Expense (NNE)	83	113	141	191	229	278	357	582	243	154
Net Nonoperating Obligations (NNO)	-1,332	-952	-1,705	-1,099	-1,551	-1,724	-1,801	-1,225	-1,468	-1,738
Total Depreciation and Amortization (D&A)	19	15	12	15	54	74	90	44	54	57
Debt-free, Cash-free Net Working Capital to Revenue	-90.62%	-183.68%	-78.00%	-84.04%	-78.68%	31.47%	-38.22%	-25.84%	-23.22%	-26.04%
Debt-free Net Working Capital to Revenue	2,538.60%	1,145.44%	1,802.31%	1,363.28%	620.37%	411.79%	250.25%	185.49%	110.21%	93.81%
Net Working Capital to Revenue	2,538.60%	1,145.44%	1,802.31%	1,363.28%	620.37%	411.79%	250.25%	185.49%	110.21%	93.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.45)	($4.79)	($5.42)	($7.57)	($8.11)	($7.46)	($7.20)	($9.30)	($3.52)	($2.18)
Adjusted Weighted Average Basic Shares Outstanding	85.14M	86.01M	99.87M	106.26M	112.58M	117.00M	118.45M	121.69M	124.91M	127.65M
Adjusted Diluted Earnings per Share	($3.45)	($4.79)	($5.42)	($7.57)	($8.11)	($7.46)	($7.20)	($9.30)	($3.52)	($2.18)
Adjusted Weighted Average Diluted Shares Outstanding	85.14M	86.01M	99.87M	106.26M	112.58M	117.00M	118.45M	121.69M	124.91M	127.65M
Adjusted Basic & Diluted Earnings per Share	($3.45)	($4.79)	($5.42)	($7.57)	($8.11)	($7.46)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	83.99M	85.60M	90.55M	100.59M	109.26M	114.99M	120.21M	124.13M	125.95M	129.46M
Normalized Net Operating Profit after Tax (NOPAT)	-207	-297	-350	-570	-658	-580	-496	-550	-198	-124
Normalized NOPAT Margin	-504.19%	-630.23%	-389.34%	-761.30%	-299.25%	-117.66%	-58.75%	-52.97%	-10.80%	-5.51%
Pre Tax Income Margin	-705.83%	-869.63%	-545.95%	-1,015.48%	-402.85%	-173.60%	-100.93%	-108.63%	-23.71%	-16.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-9.13	-4.97	-3.95	-3.36	-2.52
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-6.86	-3.47	-2.36	-1.63	-0.87
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-9.96	-5.50	-4.26	-3.88	-2.76
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-7.70	-4.00	-2.67	-2.14	-1.11
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	40.86%	29.59%	49.72%	41.78%	183.96%	31.25%	54.82%	107.00%	-33.26%	34.90%	20.20%
EBITDA Growth	-95.71%	12.94%	23.70%	-13.14%	165.26%	30.30%	76.11%	107.28%	-144.17%	-39.40%	61.27%
EBIT Growth	-80.59%	14.88%	18.15%	-13.37%	152.76%	28.47%	64.22%	97.33%	-168.14%	-36.01%	45.46%
NOPAT Growth	-42.03%	3.06%	-2.10%	-19.90%	216.05%	38.28%	71.01%	121.15%	-125.68%	9.66%	141.62%
Net Income Growth	-98.48%	19.72%	27.56%	0.50%	136.40%	33.55%	62.13%	93.88%	-175.51%	39.24%	12.82%
EPS Growth	-93.02%	21.76%	30.00%	3.49%	134.64%	37.28%	62.86%	94.12%	-175.65%	37.74%	15.38%
Operating Cash Flow Growth	13.99%	12.10%	2.76%	51.97%	411.76%	77.42%	51.03%	310.49%	-87.84%	-217.71%	-45.14%
Free Cash Flow Firm Growth	-98.36%	-89.56%	-88.45%	-94.39%	6,551.30%	482.15%	319.44%	561.59%	-69.15%	-140.55%	-120.21%
Invested Capital Growth	-15.89%	-14.06%	-13.21%	-14.54%	-17.22%	-22.09%	-18.86%	-10.58%	-11.93%	1.02%	3.61%
Revenue Q/Q Growth	17.56%	26.76%	-4.70%	-0.17%	135.46%	-41.41%	12.42%	33.48%	-24.08%	18.42%	0.17%
EBITDA Q/Q Growth	-28.88%	35.79%	18.23%	-77.82%	174.33%	-168.58%	71.19%	154.17%	-551.08%	-116.43%	89.98%
EBIT Q/Q Growth	-26.56%	35.43%	15.23%	-63.67%	158.89%	-187.55%	57.60%	87.77%	-1,400.96%	-74.76%	83.00%
NOPAT Q/Q Growth	-34.62%	26.91%	20.57%	-53.42%	230.30%	-138.87%	62.69%	211.92%	-258.20%	-36.74%	117.19%
Net Income Q/Q Growth	-46.33%	48.88%	16.09%	-58.54%	153.53%	-193.31%	52.18%	74.39%	-560.61%	24.92%	31.38%
EPS Q/Q Growth	-44.98%	49.10%	17.16%	-57.86%	152.04%	-192.17%	50.94%	75.00%	-569.23%	24.14%	33.33%
Operating Cash Flow Q/Q Growth	6.14%	-14.48%	-26.14%	64.57%	709.32%	-108.29%	-173.59%	252.31%	-64.80%	-316.58%	-24.99%
Free Cash Flow Firm Q/Q Growth	-98.71%	475.37%	40.22%	-46.16%	1,431.15%	-49.64%	1.03%	-15.07%	-28.61%	-166.20%	49.66%
Invested Capital Q/Q Growth	-4.60%	-1.22%	1.57%	-9.90%	-7.05%	-5.43%	4.17%	-2.24%	-8.37%	6.77%	6.68%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	84.44%	84.70%	82.82%	73.22%	88.77%	80.47%	86.65%	89.59%	82.85%	82.67%	88.04%
EBITDA Margin	-104.21%	-52.79%	-42.59%	-75.86%	23.95%	-28.03%	-6.57%	2.67%	-15.85%	-28.97%	-2.90%
Operating Margin	-97.63%	-56.30%	-46.92%	-72.10%	28.50%	-26.47%	-8.79%	7.37%	-15.35%	-17.73%	3.04%
EBIT Margin	-112.03%	-57.06%	-50.76%	-83.21%	20.81%	-31.10%	-11.73%	-1.07%	-21.25%	-31.36%	-5.32%
Profit (Net Income) Margin	-153.58%	-61.93%	-54.53%	-86.59%	19.69%	-31.35%	-13.34%	-2.56%	-22.27%	-14.12%	-9.67%
Tax Burden Percent	99.99%	100.23%	101.01%	100.66%	98.02%	100.13%	103.69%	151.24%	102.68%	43.19%	138.18%
Interest Burden Percent	137.10%	108.28%	106.36%	103.38%	96.50%	100.68%	109.67%	157.48%	102.10%	104.28%	131.54%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	1.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-343.51%	-526.14%	-1,500.66%	916.48%	436.71%	232.40%	138.80%	35.48%	497.73%	362.29%	519.47%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-30.72%	-16.47%	-17.01%	-30.59%	9.73%	-15.42%	-6.51%	-0.68%	-11.07%	-17.47%	-3.11%
Return on Assets (ROA)	-42.12%	-17.87%	-18.27%	-31.83%	9.20%	-15.54%	-7.41%	-1.62%	-11.60%	-7.87%	-5.65%
Return on Common Equity (ROCE)	-343.51%	-526.14%	-1,500.66%	916.48%	436.71%	232.40%	138.80%	35.48%	497.73%	362.29%	519.47%
Return on Equity Simple (ROE_SIMPLE)	1,747.72%	0.00%	410.78%	260.59%	307.40%	0.00%	151.44%	2,378.25%	-1,026.96%	0.00%	-233.64%
Net Operating Profit after Tax (NOPAT)	-181	-132	-105	-161	210	-81	-30	34	-54	-74	13
NOPAT Margin	-68.34%	-39.41%	-32.84%	-50.47%	27.93%	-18.53%	-6.15%	5.16%	-10.75%	-12.41%	2.13%
Net Nonoperating Expense Percent (NNEP)	-13.93%	-4.99%	-5.12%	-8.96%	-4.53%	-4.19%	-2.84%	-3.72%	-3.54%	-0.63%	-4.56%
Return On Investment Capital (ROIC_SIMPLE)	-	-15.38%	-	-	-	-10.18%	-	-	-	-6.74%	1.11%
Cost of Revenue to Revenue	15.56%	15.30%	17.18%	26.78%	11.23%	19.53%	13.35%	10.41%	17.15%	17.33%	11.96%
SG&A Expenses to Revenue	89.24%	62.78%	57.52%	67.35%	26.54%	45.06%	42.64%	37.65%	44.12%	49.79%	40.38%
R&D to Revenue	92.84%	78.21%	72.21%	77.97%	33.73%	61.89%	52.80%	44.58%	54.09%	50.60%	44.62%
Operating Expenses to Revenue	182.07%	141.00%	129.73%	145.32%	60.27%	106.95%	95.44%	82.22%	98.20%	100.39%	85.00%
Earnings before Interest and Taxes (EBIT)	-296	-191	-162	-265	156	-137	-58	-7.09	-106	-186	-32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-275	-177	-136	-242	180	-123	-32	18	-79	-172	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,091.32	452.40	302.82
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,091.32	452.40	302.82
Price to Revenue (P/Rev)	25.00	28.18	21.75	19.11	12.84	13.14	9.36	13.11	16.86	13.50	14.89
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	23.65	27.00	20.78	18.24	12.01	12.34	8.66	12.41	15.98	12.73	14.17
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	558.63	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	404.82	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	10,492.53	216.53	91.77	78.13	592.05	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	208.74	129.78	126.41	563.66	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-15.02	-6.43	-3.93	-2.50	-6.15	-4.63	-4.66	-333.45	31.64	15.27	8.88
Long-Term Debt to Equity	-15.02	-6.43	-3.93	-2.50	-6.15	-4.63	-4.66	-333.45	31.64	15.27	8.88
Financial Leverage	-4.70	-7.04	-19.07	11.07	11.71	7.11	5.23	6.66	24.43	20.88	29.61
Leverage Ratio	10.18	16.72	48.09	-29.01	-31.58	-19.47	-15.08	-18.03	-60.25	-52.55	-77.41
Compound Leverage Factor	13.96	18.11	51.15	-29.99	-30.48	-19.60	-16.54	-28.39	-61.51	-54.80	-101.83
Debt to Total Capital	107.13%	118.43%	134.17%	166.83%	119.42%	127.58%	127.33%	100.30%	96.94%	93.85%	89.88%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	107.13%	118.43%	134.17%	166.83%	119.42%	127.58%	127.33%	100.30%	96.94%	93.85%	89.88%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-7.13%	-18.43%	-34.17%	-66.83%	-19.42%	-27.58%	-27.33%	-0.30%	3.06%	6.15%	10.12%
Debt to EBITDA	-1.17	-1.16	-1.29	-1.24	-2.80	-2.89	-4.93	19.64	-4.94	-3.41	-3.75
Net Debt to EBITDA	1.49	1.40	1.39	1.33	3.94	4.15	6.75	-31.72	8.81	5.78	6.12
Long-Term Debt to EBITDA	-1.17	-1.16	-1.29	-1.24	-2.80	-2.89	-4.93	19.64	-4.94	-3.41	-3.75
Debt to NOPAT	-1.83	-1.85	-1.85	-1.76	-4.11	-5.17	-8.30	14.23	-7.77	-8.28	-12.70
Net Debt to NOPAT	2.35	2.23	2.00	1.88	5.79	7.43	11.37	-22.98	13.86	14.04	20.74
Long-Term Debt to NOPAT	-1.83	-1.85	-1.85	-1.76	-4.11	-5.17	-8.30	14.23	-7.77	-8.28	-12.70
Altman Z-Score	2.13	2.91	2.14	1.55	2.03	1.99	1.31	3.33	3.70	2.94	3.83
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.48	3.51	3.77	3.20	3.14	3.08	3.17	3.01	2.75	2.78	3.04
Quick Ratio	3.17	3.16	3.40	2.89	2.88	2.86	2.86	2.78	2.57	2.61	2.84
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	6.69	38	54	29	445	224	226	192	137	-91	-46
Operating Cash Flow to CapEx	-698.27%	-610.02%	-1,198.44%	-370.54%	2,102.81%	-194.62%	-628.34%	1,548.49%	1,042.63%	-1,040.93%	-1,319.00%
Free Cash Flow to Firm to Interest Expense	0.06	1.29	1.86	0.97	14.40	7.15	6.42	5.78	3.99	-2.33	-1.18
Operating Cash Flow to Interest Expense	-0.98	-4.41	-5.75	-1.96	11.63	-0.95	-2.31	3.73	1.27	-2.43	-3.06
Operating Cash Flow Less CapEx to Interest Expense	-1.12	-5.14	-6.23	-2.49	11.08	-1.44	-2.68	3.49	1.15	-2.66	-3.29
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.27	0.29	0.34	0.37	0.47	0.50	0.56	0.63	0.52	0.56	0.58
Accounts Receivable Turnover	5.90	4.75	6.08	6.82	6.76	6.46	7.41	8.84	6.17	6.13	6.35
Inventory Turnover	1.45	1.57	1.79	2.46	2.61	2.85	2.85	3.31	3.57	3.86	4.12
Fixed Asset Turnover	1.92	2.02	2.23	2.39	3.31	3.48	3.83	4.49	4.06	4.37	4.59
Accounts Payable Turnover	3.85	1.97	3.21	4.15	4.82	4.04	4.58	4.56	4.24	4.49	3.74
Days Sales Outstanding (DSO)	61.83	76.79	60.01	53.52	54.00	56.47	49.27	41.27	59.18	59.51	57.47
Days Inventory Outstanding (DIO)	250.90	232.78	204.18	148.61	139.79	128.23	128.21	110.43	102.30	94.62	88.67
Days Payable Outstanding (DPO)	94.79	185.42	113.69	88.00	75.70	90.32	79.69	80.06	86.15	81.23	97.55
Cash Conversion Cycle (CCC)	217.94	124.15	150.49	114.14	118.08	94.39	97.79	71.63	75.33	72.90	48.59
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1,366	-1,383	-1,361	-1,496	-1,602	-1,689	-1,618	-1,654	-1,793	-1,671	-1,560
Invested Capital Turnover	-0.76	-0.80	-0.89	-0.88	-1.16	-1.19	-1.34	-1.49	-1.23	-1.34	-1.48
Increase / (Decrease) in Invested Capital	-187	-171	-159	-190	-235	-306	-257	-158	-191	17	58
Enterprise Value (EV)	22,726	28,013	23,764	22,564	20,702	22,553	17,356	29,086	33,483	28,612	33,281
Market Capitalization	24,025	29,238	24,866	23,652	22,138	24,021	18,755	30,738	35,308	30,350	34,956
Book Value per Share	($0.56)	($1.29)	($2.09)	($3.28)	($1.33)	($1.76)	($1.74)	($0.02)	$0.25	$0.52	$0.89
Tangible Book Value per Share	($0.56)	($1.29)	($2.09)	($3.28)	($1.33)	($1.76)	($1.74)	($0.02)	$0.25	$0.52	$0.89
Total Capital	948	859	759	611	854	800	802	1,020	1,056	1,092	1,141
Total Debt	1,016	1,017	1,018	1,019	1,020	1,021	1,022	1,023	1,024	1,025	1,026
Total Long-Term Debt	1,016	1,017	1,018	1,019	1,020	1,021	1,022	1,023	1,024	1,025	1,026
Net Debt	-1,299	-1,225	-1,102	-1,088	-1,436	-1,468	-1,399	-1,651	-1,825	-1,738	-1,675
Capital Expenditures (CapEx)	17	22	14	16	17	15	13	8.02	4.19	9.09	8.97
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-347	-268	-203	-322	-371	-424	-324	-507	-645	-585	-440
Debt-free Net Working Capital (DFNWC)	1,918	1,924	1,868	1,735	2,036	2,015	2,047	2,118	2,135	2,109	2,193
Net Working Capital (NWC)	1,918	1,924	1,868	1,735	2,036	2,015	2,047	2,118	2,135	2,109	2,193
Net Nonoperating Expense (NNE)	225	75	69	115	62	56	36	51	58	10	70
Net Nonoperating Obligations (NNO)	-1,299	-1,225	-1,102	-1,088	-1,436	-1,468	-1,399	-1,651	-1,825	-1,738	-1,675
Total Depreciation and Amortization (D&A)	21	14	26	23	24	13	25	25	27	14	14
Debt-free, Cash-free Net Working Capital to Revenue	-36.14%	-25.84%	-17.76%	-26.03%	-21.50%	-23.22%	-16.19%	-21.63%	-30.81%	-26.04%	-18.72%
Debt-free Net Working Capital to Revenue	199.61%	185.49%	163.33%	140.25%	118.10%	110.21%	102.17%	90.33%	101.91%	93.81%	93.38%
Net Working Capital to Revenue	199.61%	185.49%	163.33%	140.25%	118.10%	110.21%	102.17%	90.33%	101.91%	93.81%	93.38%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.32)	($1.69)	($1.40)	($2.21)	$1.18	($1.09)	($0.52)	($0.13)	($0.87)	($0.66)	($0.44)
Adjusted Weighted Average Basic Shares Outstanding	122.17M	121.69M	124.11M	124.66M	125.22M	124.91M	126.14M	126.73M	128.59M	127.65M	129.68M
Adjusted Diluted Earnings per Share	($3.32)	($1.69)	($1.40)	($2.21)	$1.15	($1.06)	($0.52)	($0.13)	($0.87)	($0.66)	($0.44)
Adjusted Weighted Average Diluted Shares Outstanding	122.17M	121.69M	124.11M	124.66M	131.34M	124.91M	126.14M	126.73M	128.59M	127.65M	129.68M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	123.03M	124.13M	124.53M	125.00M	125.49M	125.95M	126.49M	128.38M	128.98M	129.46M	130.39M
Normalized Net Operating Profit after Tax (NOPAT)	-181	-132	-105	-161	210	-81	-30	34	-54	-74	13
Normalized NOPAT Margin	-68.34%	-39.41%	-32.84%	-50.47%	27.93%	-18.53%	-6.15%	5.16%	-10.75%	-12.41%	2.13%
Pre Tax Income Margin	-153.59%	-61.79%	-53.98%	-86.03%	20.08%	-31.31%	-12.86%	-1.69%	-21.69%	-32.70%	-7.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.52	-6.39	-5.60	-8.83	5.06	-4.36	-1.64	-0.21	-3.10	-4.77	-0.82
NOPAT to Interest Expense	-1.54	-4.41	-3.62	-5.36	6.79	-2.60	-0.86	1.02	-1.57	-1.89	0.33
EBIT Less CapEx to Interest Expense	-2.66	-7.11	-6.08	-9.36	4.50	-4.85	-2.01	-0.45	-3.22	-5.01	-1.05
NOPAT Less CapEx to Interest Expense	-1.68	-5.14	-4.10	-5.89	6.23	-3.09	-1.23	0.78	-1.69	-2.12	0.10
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

Alnylam Pharmaceuticals (NASDAQ: ALNY) has shown mixed financial performance over the past few years through Q1 2025, with recent quarters revealing signs of stabilization but persistent net losses.

Positive trends observed:

Operating revenue rose steadily from $264 million in Q3 2022 to about $594 million in Q1 2025, demonstrating top-line growth.
Gross profit improved correspondingly, reaching $523 million in Q1 2025 compared to $223 million in Q3 2022, indicating improved production efficiencies or pricing power.
Alnylam maintained strong cash and equivalents, increasing notably to $1.02 billion by Q1 2025 from roughly $1 billion in Q3 2023, supporting liquidity.
The company consistently generated positive net cash from investing activities in recent quarters, suggesting effective asset management and investment strategies.
Issuance of common equity added capital throughout these periods, with $49 million raised in Q1 2025, enhancing financial flexibility.

Neutral observations:

Research & Development expenses remain high and relatively steady around $230 million to $295 million per quarter, reflecting ongoing investment but also steady cost pressure.
Selling, General & Administrative (SG&A) expenses fluctuated but stayed around the $200-295 million quarterly range, indicating consistent operating costs.
Interest expenses are significant, roughly in the $29-$39 million range per quarter, which impacts profitability but is somewhat offset by interest income.

Negative trends to monitor:

Net income remains negative every quarter, including a net loss of $57 million in Q1 2025, despite improvements in revenue and gross profit.
Operating income has been weak or negative in many recent quarters, reflecting high operating expenses relative to revenues.
Total liabilities consistently outpace total equity, with the company carrying over $4 billion in liabilities and only about $115 million in equity at Q1 2025, indicating a leveraged balance sheet.
Changes in operating capital have negatively impacted cash flows, with significant outflows shown in several quarters, including Q1 2025 (-$168 million).
Despite revenue growth, earnings per share (EPS) have remained negative throughout 2023 and early 2025 periods, indicating ongoing unprofitability on a per-share basis.

Summary: Alnylam Pharmaceuticals has exhibited robust revenue and gross profit growth over the last few years, supported by strong cash reserves and capital raising activities. However, the company continues to face significant net losses and operating challenges that pressure earnings and cash flows. High R&D and SG&A expenses weigh on operating income, and the leveraged balance sheet warrants attention. Investors should watch for future quarters to see if revenue growth can translate into sustained profitability and improved shareholder equity.

08/04/25 11:16 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Alnylam Pharmaceuticals' Financials

When does Alnylam Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Alnylam Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Alnylam Pharmaceuticals' net income changed over the last 9 years?

Alnylam Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$278.16 million in 2024, falling from -$290.07 million in 2015. The previous period was -$440.24 million in 2023. Find out what analysts predict for Alnylam Pharmaceuticals in the coming months.

What is Alnylam Pharmaceuticals' operating income?

Alnylam Pharmaceuticals' total operating income in 2024 was -$176.89 million, based on the following breakdown:

Total Gross Profit: $1.92 billion
Total Operating Expenses: $2.10 billion

How has Alnylam Pharmaceuticals' revenue changed over the last 9 years?

Over the last 9 years, Alnylam Pharmaceuticals' total revenue changed from $41.10 million in 2015 to $2.25 billion in 2024, a change of 5,370.6%.

How much debt does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals' total liabilities were at $4.17 billion at the end of 2024, a 3.0% increase from 2023, and a 3,326.1% increase since 2015.

How much cash does Alnylam Pharmaceuticals have?

In the past 9 years, Alnylam Pharmaceuticals' cash and equivalents has ranged from $180.90 million in 2015 to $966.43 million in 2024, and is currently $966.43 million as of their latest financial filing in 2024.

How has Alnylam Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Alnylam Pharmaceuticals' book value per share changed from 14.93 in 2015 to 0.52 in 2024, a change of -96.5%.

Related Companies

This page (NASDAQ:ALNY) was last updated on 8/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Financials

Key Financial Trends

Frequently Asked Questions About Alnylam Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Financials

Annual Income Statements for Alnylam Pharmaceuticals

Quarterly Income Statements for Alnylam Pharmaceuticals

Annual Cash Flow Statements for Alnylam Pharmaceuticals

Quarterly Cash Flow Statements for Alnylam Pharmaceuticals

Annual Balance Sheets for Alnylam Pharmaceuticals

Quarterly Balance Sheets for Alnylam Pharmaceuticals

Annual Metrics And Ratios for Alnylam Pharmaceuticals

Quarterly Metrics And Ratios for Alnylam Pharmaceuticals

Key Financial Trends

Frequently Asked Questions About Alnylam Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools